Summary
Thermo Fisher Scientific Inc. (TMO), formerly Thermo Electron Corporation, reported solid performance for the fiscal year ended December 30, 2004, demonstrating revenue growth and improved operating income. The company's strategic focus on its core instrument businesses, supported by both internal development and strategic acquisitions, appears to be driving positive results. Management highlighted a 16% revenue increase driven by currency translation, acquisitions, and a 4% organic sales increase attributed to recovery in the U.S. and Asian economies and new product introductions. The company is actively managing its portfolio, having divested non-core assets and focused on its Life and Laboratory Sciences and Measurement and Control segments. The planned acquisition of Kendro Laboratory Products for $833.5 million signals continued ambition for inorganic growth. Investors should note the company's strong commitment to research and development, with significant spending in this area, and its ongoing efforts to optimize operational efficiency and productivity. While facing competitive markets and technological shifts, Thermo Fisher appears well-positioned to leverage its diversified product offerings and global reach.
Key Highlights
- 1Reported a 16% increase in revenue to $2.206 billion for the fiscal year ended December 30, 2004, driven by acquisitions, currency translation, and a 4% organic sales increase.
- 2Operating income improved to $237.5 million from $187.4 million in the prior year, with the operating income margin expanding to 10.8% from 9.9%.
- 3Successfully integrated several acquisitions in 2003 and 2004, including InnaPhase Corporation and US Counseling Services, Inc., to strengthen its Life and Laboratory Sciences segment.
- 4Announced a significant $833.5 million agreement to acquire Kendro Laboratory Products, indicating continued aggressive growth strategy.
- 5Maintained a strong focus on research and development, with $134.7 million spent in 2004, underscoring commitment to technological advancement and new product introductions.
- 6The company divested its Optical Technologies segment (Spectra-Physics) in July 2004, further streamlining its operations to focus on core instrument businesses.
- 7Backlog for continuing operations increased to $467.0 million at year-end 2004, up from $370.0 million in 2003, signaling strong future demand.